I am also copying in some thoughts from
@Santiago Palacios that was shared via email. Hopefully the uploaded summary captures these points. Please let me know if not or something you would still add/ react to this.
_1. Underutilization Driven by Awareness, Not by Clinical Limitations
One of the most relevant conclusions is that Evra® is significantly underoffered in routine contraceptive counselling. This appears to be primarily an educational gap rather than a limitation of the method itself. In my opinion, increasing physician awareness—especially among younger clinicians and trainees—should be a priority, as familiarity strongly influences prescribing behavior.
Strong Value Proposition in Adherence and Lifestyle Fit
The weekly administration and the 48-hour flexibility window represent a clear and meaningful advantage over daily oral contraceptives. In real-world practice, adherence is one of the main determinants of contraceptive success, and Evra® addresses this effectively. This makes it particularly suitable for busy, professionally active women and younger patients with poor pill compliance.
Importance of Proper Counselling
The discussion around visibility, adhesion, and patient perception is highly relevant. These are not true limitations but rather counselling challenges. When appropriately explained—placement options, reassurance about adhesion, and management in different climates—these concerns can be minimized, improving both acceptance and continuation rates.
Safety Perception vs. Reality
The gap between perceived and actual VTE risk remains a critical issue. As highlighted, baseline risk is largely driven by patient factors such as BMI rather than the contraceptive method itself. Updated real-world data (e.g., Danish registry data) should be actively incorporated into educational materials to correct outdated perceptions and support evidence-based decision-making.
Clear Niche Patient Profiles
The document correctly identifies patient groups that can particularly benefit from the patch:
Women with gastrointestinal disorders or impaired absorption
Women with adherence challenges
Women seeking non-invasive, user-controlled methods
Patients on treatments that may interfere with oral absorption (e.g., GLP-1 analogues)
In addition, I would highlight its potential relevance in perimenopausal women, where cycle control, convenience, and avoidance of daily medication can be particularly valuable—although more data in this group would be welcome.
Research Opportunities Are Well Identified
The proposed research gaps are appropriate and clinically meaningful. I would particularly support:
More real-world data on quality of life and satisfaction
Inclusion of sexual function as a key endpoint
Studies in switcher populations, as they reflect real clinical scenarios
Better characterization of BMI-related efficacy and risk, ideally moving beyond simple weight cut-offs
Need for Practical Tools and Patient Education
The suggestion to develop simple, practical counselling tools is highly relevant. In daily practice, short, clear educational materials (leaflets, digital content, or even brief videos/podcasts) can significantly improve both physician confidence and patient uptake.
Conclusion
Evra® is a highly effective and well-established contraceptive option with clear advantages in adherence and patient convenience. However, its full potential is currently limited by low awareness and persistent misconceptions rather than clinical shortcomings.
Improving education—both for healthcare professionals and patients—together with updated real-world evidence and practical counselling tools, will be key to increasing its appropriate use in clinical practice.
_
You don't have permission to do this.
You're going a bit too fast! Take a break and try again in a moment.
Something went wrong! Please reload the page and try again.
Your session has expired. Please reload the page and try again.
Richter Gedeon
I am also copying in some thoughts from @Santiago Palacios that was shared via email. Hopefully the uploaded summary captures these points. Please let me know if not or something you would still add/ react to this.
_1. Underutilization Driven by Awareness, Not by Clinical Limitations
One of the most relevant conclusions is that Evra® is significantly underoffered in routine contraceptive counselling. This appears to be primarily an educational gap rather than a limitation of the method itself. In my opinion, increasing physician awareness—especially among younger clinicians and trainees—should be a priority, as familiarity strongly influences prescribing behavior.
Strong Value Proposition in Adherence and Lifestyle Fit
The weekly administration and the 48-hour flexibility window represent a clear and meaningful advantage over daily oral contraceptives. In real-world practice, adherence is one of the main determinants of contraceptive success, and Evra® addresses this effectively. This makes it particularly suitable for busy, professionally active women and younger patients with poor pill compliance.
Importance of Proper Counselling
The discussion around visibility, adhesion, and patient perception is highly relevant. These are not true limitations but rather counselling challenges. When appropriately explained—placement options, reassurance about adhesion, and management in different climates—these concerns can be minimized, improving both acceptance and continuation rates.
Safety Perception vs. Reality
The gap between perceived and actual VTE risk remains a critical issue. As highlighted, baseline risk is largely driven by patient factors such as BMI rather than the contraceptive method itself. Updated real-world data (e.g., Danish registry data) should be actively incorporated into educational materials to correct outdated perceptions and support evidence-based decision-making.
Clear Niche Patient Profiles
The document correctly identifies patient groups that can particularly benefit from the patch:
Women with gastrointestinal disorders or impaired absorption
Women with adherence challenges
Women seeking non-invasive, user-controlled methods
Patients on treatments that may interfere with oral absorption (e.g., GLP-1 analogues)
In addition, I would highlight its potential relevance in perimenopausal women, where cycle control, convenience, and avoidance of daily medication can be particularly valuable—although more data in this group would be welcome.
The proposed research gaps are appropriate and clinically meaningful. I would particularly support:
More real-world data on quality of life and satisfaction
Inclusion of sexual function as a key endpoint
Studies in switcher populations, as they reflect real clinical scenarios
Better characterization of BMI-related efficacy and risk, ideally moving beyond simple weight cut-offs
The suggestion to develop simple, practical counselling tools is highly relevant. In daily practice, short, clear educational materials (leaflets, digital content, or even brief videos/podcasts) can significantly improve both physician confidence and patient uptake.
Conclusion
Evra® is a highly effective and well-established contraceptive option with clear advantages in adherence and patient convenience. However, its full potential is currently limited by low awareness and persistent misconceptions rather than clinical shortcomings.
Improving education—both for healthcare professionals and patients—together with updated real-world evidence and practical counselling tools, will be key to increasing its appropriate use in clinical practice.
_